Cargando…

FOXF1 is required for the oncogenic properties of PAX3-FOXO1 in rhabdomyosarcoma.

The PAX3-FOXO1 fusion protein is the key oncogenic driver in fusion positive rhabdomyosarcoma (FP-RMS), an aggressive soft tissue malignancy with a particularly poor prognosis. Identifying key downstream targets of PAX3-FOXO1 will provide new therapeutic opportunities for treatment of FP-RMS. Herein...

Descripción completa

Detalles Bibliográficos
Autores principales:	Milewski, David, Shukla, Samriddhi, Gryder, Berkley E., Pradhan, Arun, Donovan, Johnny, Sudha, Parvathi, Vallabh, Sushmitha, Pyros, Athena, Xu, Yan, Barski, Artem, Szabo, Sara, Turpin, Brian, Pressey, Joseph G., Millay, Douglas P., Khan, Javed, Kalinichenko, Vladimir V., Kalin, Tanya V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8005492/ https://www.ncbi.nlm.nih.gov/pubmed/33627785 http://dx.doi.org/10.1038/s41388-021-01694-9

Ejemplares similares

FoxF1 and FoxF2 transcription factors synergistically promote Rhabdomyosarcoma carcinogenesis by repressing transcription of p21(Cip1) CDK inhibitor
por: Milewski, David, et al.
Publicado: (2016)

FOXF1 transcription factor promotes lung regeneration after partial pneumonectomy
por: Bolte, Craig, et al.
Publicado: (2017)

Lung endothelial cells regulate pulmonary fibrosis through FOXF1/R-Ras signaling
por: Bian, Fenghua, et al.
Publicado: (2023)

FOXF1 Inhibits Pulmonary Fibrosis by Preventing CDH2-CDH11 Cadherin Switch in Myofibroblasts
por: Black, Markaisa, et al.
Publicado: (2018)

Improving anti-tumor efficacy of low-dose Vincristine in rhabdomyosarcoma via the combination therapy with FOXM1 inhibitor RCM1
por: Donovan, Johnny, et al.
Publicado: (2023)

Corrigendum: Improving anti-tumor efficacy of low-dose Vincristine in rhabdomyosarcoma via the combination therapy with FOXM1 inhibitor RCM1
por: Donovan, Johnny, et al.
Publicado: (2023)

Identification of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma
por: AHN, EUN HYUN, et al.
Publicado: (2013)

Forkhead transcription factor FoxF1 interacts with Fanconi anemia protein complexes to promote DNA damage response
por: Pradhan, Arun, et al.
Publicado: (2015)

Alveolar rhabdomyosarcoma – The molecular drivers of PAX3/7-FOXO1-induced tumorigenesis
por: Marshall, Amy D, et al.
Publicado: (2012)

Negative correlation of single-cell PAX3:FOXO1 expression with tumorigenicity in rhabdomyosarcoma
por: Regina, Carla, et al.
Publicado: (2021)

PAX3-FOXO1 dictates myogenic reprogramming and rhabdomyosarcoma identity in endothelial progenitors
por: Searcy, Madeline B., et al.
Publicado: (2023)

The PAX3-FOXO1 Fusion Protein Present in Rhabdomyosarcoma Interferes with Normal FOXO Activity and the TGF-β Pathway
por: Schmitt-Ney, Michel, et al.
Publicado: (2015)

Therapeutic Approaches Targeting PAX3-FOXO1 and Its Regulatory and Transcriptional Pathways in Rhabdomyosarcoma
por: Nguyen, Thanh Hung, et al.
Publicado: (2018)

MS-275 (Entinostat) Promotes Radio-Sensitivity in PAX3-FOXO1 Rhabdomyosarcoma Cells
por: Cassandri, Matteo, et al.
Publicado: (2021)

FOXM1 nuclear transcription factor translocates into mitochondria and inhibits oxidative phosphorylation
por: Black, Markaisa, et al.
Publicado: (2020)

PPP2R1A regulated by PAX3/FOXO1 fusion contributes to the acquisition of aggressive behavior in PAX3/FOXO1-positive alveolar rhabdomyosarcoma
por: Akaike, Keisuke, et al.
Publicado: (2018)

Endothelial progenitor cells stimulate neonatal lung angiogenesis through FOXF1-mediated activation of BMP9/ACVRL1 signaling
por: Wang, Guolun, et al.
Publicado: (2022)

Divergent transcriptional and transforming properties of PAX3-FOXO1 and PAX7-FOXO1 paralogs
por: Manceau, Line, et al.
Publicado: (2022)

PAX3-FOXO1 transgenic zebrafish models identify HES3 as a mediator of rhabdomyosarcoma tumorigenesis
por: Kendall, Genevieve C, et al.
Publicado: (2018)

Regulatory landscape fusion in rhabdomyosarcoma through interactions between the PAX3 promoter and FOXO1 regulatory elements
por: Vicente-García, Cristina, et al.
Publicado: (2017)

Genomic and Epigenetic Complexity of the FOXF1 Locus in 16q24.1: Implications for Development and Disease
por: Dharmadhikari, Avinash V., et al.
Publicado: (2015)

A Shh-Foxf-Fgf18-Shh Molecular Circuit Regulating Palate Development
por: Xu, Jingyue, et al.
Publicado: (2016)

Modeling of the Human Alveolar Rhabdomyosarcoma Pax3-Foxo1 Chromosome Translocation in Mouse Myoblasts Using CRISPR-Cas9 Nuclease
por: Lagutina, Irina V., et al.
Publicado: (2015)

Cyclin-Dependent Kinase 4 Phosphorylates and Positively Regulates PAX3-FOXO1 in Human Alveolar Rhabdomyosarcoma Cells
por: Liu, Lingling, et al.
Publicado: (2013)

Inhibiting phosphorylation of the oncogenic PAX3-FOXO1 reduces alveolar rhabdomyosarcoma phenotypes identifying novel therapy options
por: Loupe, J M, et al.
Publicado: (2015)

OLIG2 is a novel immunohistochemical marker associated with the presence of PAX3/7-FOXO1 translocation in rhabdomyosarcomas
por: Kaleta, Magdalena, et al.
Publicado: (2019)

Mutant myogenin promoter-controlled oncolytic adenovirus selectively kills PAX3-FOXO1-positive rhabdomyosarcoma cells
por: Yoshida, Hideki, et al.
Publicado: (2020)

JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells
por: Walters, Zoë S, et al.
Publicado: (2013)

Demonstration of Safety in Wild Type Mice of npFOXF1, a Novel Nanoparticle-Based Gene Therapy for Alveolar Capillary Dysplasia with Misaligned Pulmonary Veins
por: Kohram, Fatemeh, et al.
Publicado: (2023)

Identify potential driver genes for PAX-FOXO1 fusion-negative rhabdomyosarcoma through frequent gene co-expression network mining
por: Zhan, Xiaohui, et al.
Publicado: (2023)

Comparative Analyses of Lung Transcriptomes in Patients with Alveolar Capillary Dysplasia with Misalignment of Pulmonary Veins and in Foxf1 Heterozygous Knockout Mice
por: Sen, Partha, et al.
Publicado: (2014)

Lethal lung hypoplasia and vascular defects in mice with conditional Foxf1 overexpression
por: Dharmadhikari, Avinash V., et al.
Publicado: (2016)

PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma
por: Hanna, Jason A., et al.
Publicado: (2018)

Synthetic MIR143-3p Suppresses Cell Growth in Rhabdomyosarcoma Cells by Interrupting RAS Pathways Including PAX3–FOXO1
por: Sugito, Nobuhiko, et al.
Publicado: (2020)

Reduced B7-H3 expression by PAX3-FOXO1 knockdown inhibits cellular motility and promotes myogenic differentiation in alveolar rhabdomyosarcoma
por: Kanayama, Takuyo, et al.
Publicado: (2021)

AP-1 activity induced by co-stimulation is required for chromatin opening during T cell activation
por: Yukawa, Masashi, et al.
Publicado: (2019)

Foxf Genes Integrate Tbx5 and Hedgehog Pathways in the Second Heart Field for Cardiac Septation
por: Hoffmann, Andrew D., et al.
Publicado: (2014)

Alveolar rhabdomyosarcoma: morphoproteomics and personalized tumor graft testing further define the biology of PAX3-FKHR(FOXO1) subtype and provide targeted therapeutic options
por: Brown, Robert E., et al.
Publicado: (2016)

The PAX-FOXO1s trigger fast trans-differentiation of chick embryonic neural cells into alveolar rhabdomyosarcoma with tissue invasive properties limited by S phase entry inhibition
por: Gonzalez Curto, Gloria, et al.
Publicado: (2020)

Genetic Characterization, Current Model Systems and Prognostic Stratification in PAX Fusion-Negative vs. PAX Fusion-Positive Rhabdomyosarcoma
por: Dehner, Carina A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mgej4gucn2a65bu9pifcrqqji3